个人简介

1997-2000 法国国家癌症中心乳腺专科医师培训

2005 丹麦欧登塞大学访问学者

2006 德国慕尼黑大学访问学者

2007.09--2010.06 南方医科大学博士研究生

2011.12--至今     广东省人民医院乳腺科行政主任，教授

研究方向

乳腺癌诊断及治疗；乳腺癌基因与遗传筛查；乳腺癌机器人保乳手术

代表性论著

1. Zhang W, Ning L (Corresponding author) et al. An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses. Nat Commun 2024; 15: 5670. （IF=16.6）

2. Zhang G, Ning L (Corresponding author)  et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med 2022; 20: 142.

3. Ning L (First author & corresponding author) , Li C, Cao L et al. Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node. Breast Cancer 2023; 30: 77-87.

4. Chen B, Ning L (Corresponding author) et al. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine 2021; 71: 103542

5. Gao R, Li C, Ning L et al. Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study. Endocrine 2024.

6. Ganz, P. A., Bandos, H., Ning L et al. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol 2024; 42: 1288-1300.

7. Wang J, Cai L, Song Y, Ning L et al. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). Eur J Cancer 2023; 184: 73-82.

8. Huang, L., Pang, D., Yang, H., Li, W., Wang, S., Cui, S., Liao, N., Wang, Y., Wang, C., Chang, Y. C., Wang, H. C., Kang, S. Y., Seo, J. H., Shen, K., Laohawiriyakamol, S., Jiang, Z., Wang, H., Lamour, F., Song, G., Curran, M., … Shao, Z. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nat Commun 2024; 15: 2153.

9. Li K, Ning L (Corresponding author) et al. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations. Cancer Med 2023; 12: 5195-5208.

10. Wu J, Fan D, Ning L ,Shao Z et al. CACA Guidelines for Holistic Integrative Management of Breast Cancer. Holist Integr Oncol 2022; 1: 7.

代表性课题

1.广州市科技项目，2024.1.1-2026.12.31，主持，100万，

2.国家重点研发项目，2026.1.1-2029.12.31，主持，400万

3.国家自然科学基金面上项目，2023.1.1-2026.12.31，主持，52万

4.临床重点研发项目，2025.9.18-2028.12.31，主持，250万

5.前沿生物技术专项,20221.1-2027.12.31，参与，30万

学术任职

1. 美国耶鲁大学医学院免疫学部访问学者

2. 美国肿瘤外科医师协会（SSO）国际理事会理事

3. 国际前哨淋巴结协会（ISNS）国际理事会理事

4. 美国NCCN乳腺癌指南（中文版）专家组成员

5. St Gallen国际乳腺癌指南（中文版）专家组成员

6. 美国肿瘤外科年鉴《Annals of surgical oncology》编辑委员会委员

7. 国家卫生健康委员会医政司《乳腺癌治疗规范》编写组成员

8. 国家卫生健康委员会《乳腺癌诊断指南》专家组成员

9. 国家卫生健康委员会合理用药专家委员会《肿瘤药物组》专家组成员

10. 国家癌症中心癌症筛查专家委员会乳腺癌筛查专业委员会专家组成员

11. 广东省医师协会乳腺专科医师分会主任委员

执教课程（课程及教材建设）

1. 外科学